Structural basis of a shared antibody response to SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Cited by
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.037 · Cited by 992
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147
“Class 1 antibodies are most frequently elicited by SARS-CoV-2 infection and are comprised almost entirely of immunoglobulin V-gene (VH3-53/66) germline restricted antibodies, forming a multi-donor class with highly similar epitopes only accessible in the RBD ‘up’ conformation 11,15,16 .”
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.046 · Cited by 930
“Nineteen of the twenty most potent (FRNT50 < 100 ng/mL) neutralizing mAbs are mapped to the ACE2 binding site across the neck and shoulder epitopes of the RBD, and 5 of these are classified as public IGVH3-53 (immunoglobulin heavy chain variable gene family) antibodies (Dejnirattisai et al., 2021a; Yuan et al., 2020).”
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 686
A molecular single-cell lung atlas of lethal COVID-19
Melms, J. C., Biermann, J., Huang, H., Wang, Y., Nair, A., Tagore, S., Katsyv, I., Rendeiro, A. F., Amin, A. D., Schapiro, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03569-1 · Cited by 679
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
“Most potent neutralizing antibodies bind the RBD on or closely adjacent to the ACE2-interacting surface and function to block interaction of the virus with ACE2, preventing cellular adhesion and infection (Dejnirattisai et al., 2021a; Yuan et al., 2020; Kreye et al., 2020).”
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519
Antibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
Structural biology of SARS-CoV-2 and implications for therapeutic development
Yang, H., & Rao, Z. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00630-8 · Cited by 548
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1555 · Cited by 475
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460
“There is a marked 3-fold effect for mAb 40 (IGHV3-66) and for most of the important IGHV3-53 antibodies (150, 158, and 175).”
BackgroundResultInfluentialMapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Koenig, P.-A., Das, H., Liu, H., Kümmerer, B. M., Gohr, F. N., Jenster, L.-M., Schiffelers, L. D. J., Tesfamariam, Y. M., Uchima, M., Wuerth, J. D., et al. (2021) · Science · doi:10.1126/science.abe6230 · Cited by 396
“The epitope of VHH U overlaps with the binding site of SARSCoV-1–neutralizing antibody CR3022 (17) and VHH 72 (16) (fig.”
InfluentialEffect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
Gobeil, S. M.-C., Janowska, K., McDowell, S., Mansouri, K., Parks, R., Stalls, V., Kopp, M. F., Manne, K., Li, D., Wiehe, K., et al. (2021) · Science · doi:10.1126/science.abi6226 · Cited by 394
“The Markov models were characterized by a hook-like folded RBD tip (the “Hook” state), which resembled the conformation observed in x-ray crystal structures (33, 53), and a highly dynamic “Disordered” state in which the RBD tip cycles between a variety of conformations (Fig.”
BackgroundBroadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Chen, Y., Zhao, X., Zhou, H., Zhu, H., Jiang, S., & Wang, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00784-3 · Cited by 383
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364
“The IGHV gene usage 426 in 1,593 SARS-CoV-2 RBD-targeting antibodies (12-43) compared to healthy individuals 427”
BackgroundKreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.049 · Cited by 347
“Some public or shared clonotypes had been reported previously, such as IGHV3-53 and IGHV3-66 (Figure S3D; Cao et al., 2020; Yuan et al., 2020a), whereas others were newly identified, such as IGHV3-11 (Figure S3C).”
Self-citationAli, M. A., Hu, C., Jahan, S., Yuan, B., Saleh, M. S., Ju, E., Gao, S., & Panat, R. (2021) · Advanced Materials · doi:10.1002/adma.202006647 · Cited by 343
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Hastie, K. M., Li, H., Bedinger, D., Schendel, S. L., Dennison, S. M., Li, K., Rayaprolu, V., Yu, X., Mann, C., Zandonatti, M., et al. (2021) · Science · doi:10.1126/science.abh2315 · Cited by 314
“This cryptic RBD-6/7 site is also recognized by antibodies COVA1-16 ( 23 ) and CR3022 ( 24 ).”
BackgroundSARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04778-y · Cited by 297
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00972-2 · Cited by 285
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23074-3 · Cited by 285
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
Kim, C., Ryu, D.-K., Lee, J., Kim, Y.-I., Seo, J.-M., Kim, Y.-G., Jeong, J.-H., Kim, M., Kim, J.-I., Kim, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20602-5 · Cited by 281
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Wang, Z., C. Lorenzi, J. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.008 · Cited by 277
“Class 1 antibodies are derived from VH3-53 or VH3-63 gene segments, include short CDRH3s, and recognize the ACE2 binding site on RBDs in an up conformation (Barnes et al., 2020a, 2020b; Hurlburt et al., 2020; Shi et al., 2020; Wu et al., 2020c; Yuan et al., 2020).”
BackgroundTubiana, J., Schneidman-Duhovny, D., & Wolfson, H. J. (2022) · Nature Methods · doi:10.1038/s41592-022-01490-7 · Cited by 274
Du, S., Cao, Y., Zhu, Q., Yu, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 249
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Martínez-Flores, D., Zepeda-Cervantes, J., Cruz-Reséndiz, A., Aguirre-Sampieri, S., Sampieri, A., & Vaca, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701501 · Cited by 240
Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.003 · Cited by 240
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y.-C., Lu, R.-M., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H.-C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 237
D’Agnillo, F., Walters, K.-A., Xiao, Y., Sheng, Z.-M., Scherler, K., Park, J., Gygli, S., Rosas, L. A., Sadtler, K., Kalish, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj7790 · Cited by 237
“S2) (26).”
Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2
Nielsen, S. C. A., Yang, F., Jackson, K. J. L., Hoh, R. A., Röltgen, K., Jean, G. H., Stevens, B. A., Lee, J.-Y., Rustagi, A., Rogers, A. J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.09.002 · Cited by 236
“4) from a cluster that is convergent with BD-494 (Yuan et al., 2020), pairing these with the germline-reverted BD-494 light chain and reported CDR-L3.”
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2021) · Nature · doi:10.1038/d41586-021-03796-6 · Cited by 227
Liu, H., Wu, N. C., Yuan, M., Bangaru, S., Torres, J. L., Caniels, T. G., van Schooten, J., Zhu, X., Lee, C.-C. D., Brouwer, P. J. M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.023 · Cited by 214
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
Andreano, E., Nicastri, E., Paciello, I., Pileri, P., Manganaro, N., Piccini, G., Manenti, A., Pantano, E., Kabanova, A., Troisi, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.035 · Cited by 210
“Two other nAbs employed the most common germline observed for SARS-CoV-2 nAbs, which is IGHV3-53 (Figure 5A) (Yuan et al., 2020).”
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178
“In particular, E484 is the site in the RBD where mutations usually have the largest effect on binding and neutralization—possibly because E484 is often targeted by antibodies that utilize heavy-chain germline genes that are common among anti-SARS-CoV-2 RBD antibodies, IGHV3-53 and IGHV3-66 (Barnes et al., 2020a; Grean…”
BackgroundZhou, P., Yuan, M., Song, G., Beutler, N., Shaabani, N., Huang, D., He, W.-T., Zhu, X., Callaghan, S., Yong, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9215 · Cited by 204
“The most potent nAbs in humans during natural infection are typically raised to epitopes overlapping the ACE2 binding site (32, 33, 42, 45, 46).”
BackgroundStructural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be
Mariano, G., Farthing, R. J., Lale-Farjat, S. L. M., & Bergeron, J. R. C. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.605236 · Cited by 204
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
Clark, S. A., Clark, L. E., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M. C., Regan, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.027 · Cited by 197
Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
Yuan, M., Liu, H., Wu, N. C., & Wilson, I. A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.012 · Cited by 196
“Intriguingly, SARS-CoV-2 neutralizing antibodies encoded by IGHV3-53/3 e 66 generally have a shorter complementarity-determining region (CDR) H3 compared to non-IGHV3-53/3 e 66 antibodies, with a small subset containing a more conventional, longer CDR H3 [27,28,30,35].”
InfluentialThe humoral response and antibodies against SARS-CoV-2 infection
Qi, H., Liu, B., Wang, X., & Zhang, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 191
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V. D., Li, Y., Yuan, Z., Zhang, X., Muruato, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20789-7 · Cited by 160
Zhu, X., Mannar, D., Srivastava, S. S., Berezuk, A. M., Demers, J.-P., Saville, J. W., Leopold, K., Li, W., Dimitrov, D. S., Tuttle, K. S., et al. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001237 · Cited by 178
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Nutalai, R., Zhou, D., Tuekprakhon, A., Ginn, H. M., Supasa, P., Liu, C., Huo, J., Mentzer, A. J., Duyvesteyn, H. M. E., Dijokaite-Guraliuc, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.014 · Cited by 176
Prolonged evolution of the human B cell response to SARS-CoV-2 infection
Sakharkar, M., Rappazzo, C. G., Wieland-Alter, W. F., Hsieh, C.-L., Wrapp, D., Esterman, E. S., Kaku, C. I., Wec, A. Z., Geoghegan, J. C., McLellan, J. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg6916 · Cited by 174
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Edara, V. V., Stuart, A. B., Feng, J., Suthar, M. S., McGuire, A. T., Stamatatos, L., & Pancera, M. (2020) · Nature Communications · doi:10.1038/s41467-020-19231-9 · Cited by 171
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Castro Dopico, X., Ols, S., Loré, K., & Karlsson Hedestam, G. B. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 166
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
Li, Y., Ma, M.-L., Lei, Q., Wang, F., Hong, W., Lai, D.-Y., Hou, H., Xu, Z.-W., Zhang, B., Chen, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108915 · Cited by 162
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1
Jian, F., Wang, J., Yisimayi, A., Song, W., Xu, Y., Chen, X., Niu, X., Yang, S., Yu, Y., Wang, P., et al. (2024) · Nature · doi:10.1038/s41586-024-08315-x · Cited by 182
“As mentioned above, group A1 or class 1 mAbs are predominantly derived from the IGHV3-53 and IGHV3-66 germlines, which are well known as part of the public immune response 30,32,43,44 .”
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
Wu, N. C., Yuan, M., Liu, H., Lee, C.-C. D., Zhu, X., Bangaru, S., Torres, J. L., Caniels, T. G., Brouwer, P. J. M., van Gils, M. J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108274 · Cited by 157
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants
Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., et al. (2021) · Nature · doi:10.1038/s41586-021-04117-7 · Cited by 154
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 159
Huo, J., Mikolajek, H., Bas, A. L., Clark, J. J., Sharma, P., Kipar, A., Dormon, J., Norman, C. S., Weckener, M., Clare, D. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25480-z · Cited by 153
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 152
Zhou, P., Song, G., Liu, H., Yuan, M., He, W.-T., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 150
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147
Cao, Y., Yisimayi, A., Bai, Y., Huang, W., Li, X., Zhang, Z., Yuan, T., An, R., Wang, J., Xiao, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00514-9 · Cited by 146
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 162
“…have been demonstrated to act by disrupting the spike protein (e.g., resulting in premature S1 shedding; Figure 2E) (Huo et al., 2020; Wrobel et al., 2020; Yuan et al., 2020b) and can display broad cross-reactivity against related zoonotic coronaviruses (Jette et al., 2021; Martinez et al., 2022).”
InfluentialWang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 144
“Structural analysis of the interaction betweentheseantibodies andtheRBDrevealedfourclasses of anti-RBD antibodies, each of which can interfere with the interaction between this domain and ACE2, the cellular receptor for the SARS-CoV-2 S protein (Barnes et al., 2020a; Yuan et al., 2020).”
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Pymm, P., Adair, A., Chan, L.-J., Cooney, J. P., Mordant, F. L., Allison, C. C., Lopez, E., Haycroft, E. R., O’Neill, M. T., Tan, L. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101918118 · Cited by 143
Bojadzic, D., Alcazar, O., Chen, J., Chuang, S.-T., Capcha, J. M. C., Shehadeh, L. A., & Buchwald, P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00070 · Cited by 154
Ku, M.-W., Bourgine, M., Authié, P., Lopez, J., Nemirov, K., Moncoq, F., Noirat, A., Vesin, B., Nevo, F., Blanc, C., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.12.010 · Cited by 139
“Induction of antibody responses by LVs encoding SARSCoV-2 Spike protein variants To develop a vaccine candidate able to induce NAbs against SCoV-2, we generated LVs harboring, under the transcriptional control of the cytomegalovirus (CMV) immediate-early promoter, codon-optimized sequences encoding (1) S1 alone (LV::S…”
MethodAntibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 158
Zhang, Q., Ju, B., Ge, J., Chan, J. F.-W., Cheng, L., Wang, R., Huang, W., Fang, M., Chen, P., Zhou, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24514-w · Cited by 125
Butler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Bobak, C. A., Mattox, D. E., Lee, J., Wieland‐Alter, W., Connor, R. I., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618685 · Cited by 128
Cho, H., Gonzales-Wartz, K. K., Huang, D., Yuan, M., Peterson, M., Liang, J. Y., Beutler, N., Torres, J. L., Cong, Y., Postnikova, E. N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5413 · Cited by 128
“Antibodies isolated from both plasmablasts and MBCs used diverse V genes, with many of the enriched gene families matching those previously reported (19, 24) (Fig.”
ResultMemory B cell repertoire for recognition of evolving SARS-CoV-2 spike
Tong, P., Gautam, A., Windsor, I. W., Travers, M., Chen, Y., Garcia, N., Whiteman, N. B., McKay, L. G. A., Storm, N., Malsick, L. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.025 · Cited by 120
“Enrichment for VH3-53, previously reported to be associated with SARSCoV-2 S (Yuan et al., 2020), was exclusively within the RBD-2 group.”
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 133
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 122
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey-Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 116
Neutralizing antibodies targeting SARS-CoV-2 spike protein
Shi, X., Yu, L., Yan, L., Guang, Y., & Qiang, M. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102125 · Cited by 122
“Although there are other reports summarized the germlines of 294 SAR-CoV-2 neutralizing antibodies targeting RBD from 12 published papers, it shows IGHV3-53, IGHV1-2, IGHV3-9, IGHV3-30, IGHV1-46 are the top five germlines of neutralizing antibodies, 3–30 is the fourth one (Yuan et al., 2020) (Figue 3B).”
Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies
Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Chemical Science · doi:10.1039/d1sc01203g · Cited by 115
Wang, Y., Yuan, M., Lv, H., Peng, J., Wilson, I. A., & Wu, N. C. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.019 · Cited by 109
“…by an IGHD gene with IGKV1-9 and IGHV3-53/IGKV3-20 among RBD antibodies (Cao et al., 2020; Clark et al., 2021; Kim et al., 2021; Tan et al., 2021; Yuan et al., 2020; Zhang et al., 2021; Figure 1A), as well as substantial enrichment of IGHV1-24 among NTD antibodies (Cerutti et al., 2021; Chi et…”
InfluentialStopping pandemics before they start: Lessons learned from SARS-CoV-2
Edwards, A. M., Baric, R. S., Saphire, E. O., & Ulmer, J. B. (2022) · Science · doi:10.1126/science.abn1900 · Cited by 109
Rational Vaccine Design in the Time of COVID-19
Burton, D. R., & Walker, L. M. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.022 · Cited by 106
Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 107
Bernat, N. V., Corcoran, M., Nowak, I., Kaduk, M., Dopico, X. C., Narang, S., Maisonnasse, P., Dereuddre‐Bosquet, N., Murrell, B., & Hedestam, G. B. K. (2021) · Immunity · doi:10.1016/j.immuni.2020.12.018 · Cited by 102
Zhou, D., Chan, J. F.-W., Zhou, B., Zhou, R., Li, S., Shan, S., Liu, L., Zhang, A. J., Chen, S. J., Chan, C. C.-S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.019 · Cited by 102
“In contrast, ZDY20 has IGHV3-53 and IGKV1-33, which were recently shown to be associated with higher antiviral activity (Dalamaga et al., 2020; Yuan et al., 2020).”
Huang, M., Wu, L., Zheng, A., Xie, Y., He, Q., Rong, X., Han, P., Du, P., Han, P., Zhang, Z., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.005 · Cited by 97
“As previously reported (Yuan et al., 2020b), CR3022 in RBD-7 cannot neutralize SARSCoV-2 and its variants including Delta andOmicron.”
Song, G., He, W.-T., Callaghan, S., Anzanello, F., Huang, D., Ricketts, J., Torres, J. L., Beutler, N., Peng, L., Vargas, S., et al. (2020) · doi:10.1101/2020.09.22.308965 · Cited by 285
Self-citationDeshpande, A. A., Harris, B. D., Martínez‐Sobrido, L., Kobie, J. J., & Walter, M. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691715 · Cited by 100
Guo, Y., Huang, L., Zhang, G., Yao, Y., Zhou, H., Shen, S., Shen, B., Li, B., Li, X., Zhang, Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22926-2 · Cited by 94
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Zhou, S., Tuttle, K. S., Kim, A., Li, W., Dimitrov, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110156 · Cited by 93
“Using these structural data, we evaluated the frequency of positions corresponding to RBD mutations in VoC/VoIs within the footprint of 27 selected antibodies (Banach et al., 2021; Barnes et al., 2020a, 2020b; Cao et al., 2020; Hurlburt et al., 2020; Ju et al., 2020; Kim et al., 2021; Liu et al., 2020; Piccoli et al.,…”
Papageorgiou, A. C., & Mohsin, I. (2020) · Cells · doi:10.3390/cells9112343 · Cited by 106
“1, S1 RBD [56] 7can X-ray diffraction 2.”
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
Egeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Pentelute, B. L., Carlson, J. M., Hixon, M. S., Joseph‐McCarthy, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250780 · Cited by 100
“work [11], we found that the reported epitopes show substantial overlap (Fig 1A and 1B).”
BackgroundB cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 92
“Consistent with the binding mode of class 1 nAbs (Barnes et al., 2020b; Yuan et al., 2020), BG4-25 recognizes an RBD epitope that overlaps with >90% of residues in the ACE2 RBM (Figure S6B), which is only fully accessible with ‘‘up’’ RBD conformations.”
InfluentialB-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 111
“…patients have shown that the infection-induced antibody response is highly polyclonal but that potent neutralizers are close to the germline [23, 28, 124 – 127] and show enrichment for speci fi c immunoglobulin heavy-chain variable region (IGHV) genes such as 3 – 53, 1 – 2, 3 – 9, and 3 – 30 [128].”
BackgroundValdés-Balbín, Y., Santana-Mederos, D., Quintero, L., Fernández-Castillo, S., Rodríguez, L., Ramírez, B. S., Pérez-Nicado, R., Acosta, C., Méndez, Y., Ricardo, M. G., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00272 · Cited by 85
Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses
Shrock, E. L., Timms, R. T., Kula, T., Mena, E. L., West, A. P., Guo, R., Lee, I.-H., Cohen, A. A., McKay, L. G. A., Bi, C., et al. (2023) · Science · doi:10.1126/science.adc9498 · Cited by 85
Liang, G., Cao, W., Tang, D., Zhang, H., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · ACS Nano · doi:10.1021/acsnano.3c11154 · Cited by 89
Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
Li, T., Xue, W., Zheng, Q., Song, S., Yang, C., Xiong, H., Zhang, S., Hong, M., Zhang, Y., Yu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25997-3 · Cited by 84
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H., & Sivaraman, J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.004 · Cited by 86
“33 neutralizes SARS pseudovirus SARS-2 RBD/RBM SARS RBD Likely compete with hACE-2 interface Do not compete with CR3022 Block hACE2–RBD binding Protect a hamster model 6XC2 6XC3 [27,32,34,93]”
Metadata
- Authors
- Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., Rogers, T. F., Landais, E., Sok, D., Jardine, J. G., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Wilson, Ian A.
- ORCID
- Venue
- Science
- Published
- 2020-08-28
- Volume
- 369
- Issue
- 6507
- Pages
- 1119-1123
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402627
- OpenAlex
- W3041564586
- Cited by
- 589
- References
- 53
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 55 · 2023: 64 · 2022: 133 · 2021: 203 · 2020: 51
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Institutes of Health (K99 AI139445, UM1 AI44462)
- Bill and Melinda Gates Foundation (OPP1170236)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, neutralizing antibodies, receptor binding domain, spike protein, ACE2 binding site, co-crystal structure, germline antibodies, affinity maturation, vaccine design, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.